Lixisenatide Success

Lixisenatide Success

Next possible GLP-1 diabetes drug from Sanofi-Aventis (lixisenatide) has success in a late stage trial, reducing A1c and body weight without increasing risk of hypoglycemi

BYDUREON™ recommended for approval in Europe.

BYDUREON would be first once-weekly treatment for adults with Type 2 diabetes.

Class 1 Recall of Roche Insulin Delivery Systems

Pearl Insulin Pump

| Print | Category | Home

This article originally posted 14 April, 2011 and appeared in Issue 569

2013 Most Popular Articles:

Mortality Risk in Patients with Type 2 Diabetes
Posted May 23, 2013
Hypoglycemia Treatment and Prevention Related to Physical Activity
Posted May 31, 2013
Bacteria in the Gut Improves the Management of Obesity and Type 2 Diabetes
Posted May 23, 2013
Scientist Use Bone Marrow Stem Cells to Cure Type 1 Diabetes
Posted June 06, 2013
Simvastatin Can Reduce the Benefits of Exercise in Active Adults
Posted May 23, 2013
Artificial Sweeteners May Affect Blood Glucose Levels and Insulin Response
Posted June 06, 2013
Diabetes Epidemic Growing
Posted May 23, 2013
Co-Q10 May Offset Risk of Diabetes with Statin Use
Posted May 23, 2013
Frequency of Blood Glucose Testing in Type 1's: How Often is Enough?
Posted June 13, 2013
FDA Advisory Panel Votes to Remove Avandia's Highly Restrictive Label
Posted June 06, 2013

See more most popular…

Diabetes In Control Advertisers

Cast Your Vote

If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

View All Polls »

Navigate Diabetes In Control

Cardiovascular CE & CME Clinical Slides Drugs Affecting BG Safety Tools Test Your Knowledge Medications Polls Obesity Case Studies Jobs Interviews GLP-1 Agonist Sheri R. Colberg, PhD SGLT-2

Free Weekly Newsletter
Sign up here.

Free CE Available
CE Programs on diabetes

Search Articles On Diabetes In Control

Privacy / Advertising With Us / Contact Us / UBM Medica Network Privacy Policy

Add us to your favorite news reader

DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.